Carillon Tower Advisers Inc. Buys 38,925 Shares of IDEXX Laboratories, Inc. (NASDAQ:IDXX)

Share on StockTwits

Carillon Tower Advisers Inc. raised its stake in shares of IDEXX Laboratories, Inc. (NASDAQ:IDXX) by 14.5% during the 3rd quarter, according to its most recent filing with the Securities and Exchange Commission. The institutional investor owned 306,531 shares of the company’s stock after acquiring an additional 38,925 shares during the quarter. Carillon Tower Advisers Inc. owned approximately 0.36% of IDEXX Laboratories worth $83,335,000 at the end of the most recent reporting period.

Other hedge funds and other institutional investors also recently made changes to their positions in the company. Price T Rowe Associates Inc. MD boosted its position in shares of IDEXX Laboratories by 32.9% in the 2nd quarter. Price T Rowe Associates Inc. MD now owns 3,180,724 shares of the company’s stock worth $875,749,000 after purchasing an additional 787,736 shares in the last quarter. Nuveen Asset Management LLC boosted its position in shares of IDEXX Laboratories by 27,381.7% in the 2nd quarter. Nuveen Asset Management LLC now owns 568,322 shares of the company’s stock worth $156,476,000 after purchasing an additional 566,254 shares in the last quarter. Invesco Ltd. boosted its position in shares of IDEXX Laboratories by 28.2% in the 2nd quarter. Invesco Ltd. now owns 1,472,407 shares of the company’s stock worth $405,398,000 after purchasing an additional 323,919 shares in the last quarter. Marshall Wace North America L.P. boosted its position in shares of IDEXX Laboratories by 72.8% in the 2nd quarter. Marshall Wace North America L.P. now owns 698,227 shares of the company’s stock worth $192,242,000 after purchasing an additional 294,186 shares in the last quarter. Finally, Thoroughbred Financial Services LLC boosted its position in shares of IDEXX Laboratories by 27,432.9% in the 2nd quarter. Thoroughbred Financial Services LLC now owns 257,433 shares of the company’s stock worth $25,743,000 after purchasing an additional 256,498 shares in the last quarter. 86.85% of the stock is currently owned by institutional investors and hedge funds.

A number of analysts have recently weighed in on the company. Guggenheim set a $310.00 price objective on IDEXX Laboratories and gave the stock a “buy” rating in a research report on Friday, November 1st. Stifel Nicolaus raised their target price on IDEXX Laboratories from $255.00 to $295.00 and gave the stock a “buy” rating in a research note on Monday, July 22nd. ValuEngine lowered IDEXX Laboratories from a “buy” rating to a “hold” rating in a research note on Wednesday, October 2nd. Goldman Sachs Group began coverage on IDEXX Laboratories in a research note on Monday, September 9th. They issued a “neutral” rating and a $277.00 target price for the company. Finally, Credit Suisse Group raised their target price on IDEXX Laboratories from $282.00 to $293.00 and gave the stock an “outperform” rating in a research note on Friday, August 16th. Three analysts have rated the stock with a hold rating and six have assigned a buy rating to the company. The company presently has a consensus rating of “Buy” and an average price target of $290.14.

In other news, Director Rebecca M. Henderson sold 4,000 shares of the business’s stock in a transaction that occurred on Wednesday, August 14th. The stock was sold at an average price of $271.17, for a total transaction of $1,084,680.00. Following the transaction, the director now directly owns 14,696 shares in the company, valued at approximately $3,985,114.32. The sale was disclosed in a legal filing with the SEC, which is available at the SEC website. Also, insider Jonathan W. Ayers sold 62,097 shares of the business’s stock in a transaction that occurred on Monday, November 4th. The stock was sold at an average price of $279.57, for a total value of $17,360,458.29. The disclosure for this sale can be found here. Over the last quarter, insiders sold 69,380 shares of company stock worth $19,362,310. 2.70% of the stock is currently owned by insiders.

Shares of IDXX stock opened at $254.74 on Friday. The company has a debt-to-equity ratio of 3.76, a current ratio of 1.12 and a quick ratio of 0.80. IDEXX Laboratories, Inc. has a 1 year low of $176.11 and a 1 year high of $294.57. The firm has a market capitalization of $22.66 billion, a price-to-earnings ratio of 59.80 and a beta of 0.79. The business has a fifty day moving average of $273.75 and a 200 day moving average of $268.85.

IDEXX Laboratories (NASDAQ:IDXX) last posted its quarterly earnings data on Thursday, October 31st. The company reported $1.24 earnings per share (EPS) for the quarter, topping the Thomson Reuters’ consensus estimate of $1.14 by $0.10. IDEXX Laboratories had a return on equity of 405.71% and a net margin of 17.99%. The company had revenue of $605.30 million for the quarter, compared to analysts’ expectations of $597.09 million. During the same period in the previous year, the firm posted $1.05 EPS. IDEXX Laboratories’s revenue was up 11.0% compared to the same quarter last year. As a group, equities research analysts expect that IDEXX Laboratories, Inc. will post 4.8 earnings per share for the current year.

About IDEXX Laboratories

IDEXX Laboratories, Inc, together with its subsidiaries, develops, manufactures, and distributes products and services primarily for the companion animal veterinary, livestock and poultry, dairy, and water testing markets worldwide. The company operates through Companion Animal Group; Water Quality Products; Livestock, Poultry and Dairy; and Other segments.

Featured Story: How Do I Invest in Dividend Stocks

Want to see what other hedge funds are holding IDXX? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for IDEXX Laboratories, Inc. (NASDAQ:IDXX).

Institutional Ownership by Quarter for IDEXX Laboratories (NASDAQ:IDXX)

Receive News & Ratings for IDEXX Laboratories Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for IDEXX Laboratories and related companies with MarketBeat.com's FREE daily email newsletter.

 


Latest News

Yu Darvish Receives Cortisone Shot for Elbow Impingement
Yu Darvish Receives Cortisone Shot for Elbow Impingement
Red Sox and Brandon Phillips Agree to Minor League Deal
Red Sox and Brandon Phillips Agree to Minor League Deal
Chris Sale Proves He is 2018 AL Cy Young Candidate
Chris Sale Proves He is 2018 AL Cy Young Candidate
Strong Results by Clint Frazier Could Keep Him with Yankees
Strong Results by Clint Frazier Could Keep Him with Yankees
Giants Closer Breaks Hand Punching Door Following Poor Outing
Giants Closer Breaks Hand Punching Door Following Poor Outing
Evan Longoria Out Six to Eight Weeks With Broken Hand
Evan Longoria Out Six to Eight Weeks With Broken Hand


 
© 2006-2019 BBNS.